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Background: The mechanisms by which ARF6 regulate LHCGR internalization and signaling are unknown.
Results:Heterotrimeric G-protein, PI 3-kinase, cytohesin ARF GEFs and ARF GAPs function upstream whereas dynamin and
clathrin act downstream of ARF6 in the regulation of HLHCGR internalization and signaling.
Conclusion: Dissected the molecular mechanisms underlying ARF6 involvement in LHCGR internalization and signaling.
Significance: This study provides insight into the mechanisms responsible for HLHCGR regulation by ARF6.
The luteinizing hormone chorionic gonadotropin receptor
(LHCGR) is a Gs-coupled GPCR that is essential for thematura-
tion and function of the ovary and testis. LHCGR is internalized
following its activation, which regulates the biological respon-
siveness of the receptor. Previous studies indicated that ADP-
ribosylation factor (ARF)6 and its GTP-exchange factor (GEF)
cytohesin 2 regulate LHCGR internalization in follicular mem-
branes.However, themechanismsbywhichARF6 and cytohesin
2 regulate LHCGR internalization remain incompletely under-
stood. Here we investigated the role of the ARF6 signaling path-
way in the internalization of heterologously expressed human
LHCGR (HLHCGR) in intact cells using a combination of phar-
macological inhibitors, siRNA and the expression of mutant
proteins. We found that human CG (HCG)-induced HLHCGR
internalization, cAMP accumulation and ARF6 activation were
inhibited by Gallein ( inhibitor), Wortmannin (PI 3-kinase
inhibitor), SecinH3 (cytohesin ARF GEF inhibitor), QS11 (an
ARF GAP inhibitor), an ARF6 inhibitory peptide and ARF6
siRNA. However, Dynasore (dynamin inhibitor), the dominant
negative mutants of NM23-H1 (dynamin activator) and clath-
rin, and PBP10 (PtdIns 4,5-P2-binding peptide) inhibited ago-
nist-induced HLHCGR and cAMP accumulation but not ARF6
activation. These results indicate that heterotrimericG-protein,
phosphatidylinositol (PI) 3-kinase (PI3K), cytohesin ARF GEF
andARFGAP functionupstreamofARF6whereas dynamin and
clathrin act downstream of ARF6 in the regulation of HCG-in-
duced HLHCGR internalization and signaling. In conclusion,
we have identified the components and molecular details of the
ARF6 signalingpathway required for agonist-inducedHLHCGR
internalization.
Luteinizing hormone chorionic gonadotropin receptor
(LHCGR)2 is a G-protein-coupled receptor (GPCR) that is
mainly expressed in the gonads, where it mediates LH and hCG
hormone signaling. Hence LHCGR signaling is important for
the maturation and function of the ovary and testis. GPCRs
transmit extracellular signals through heterotrimeric G pro-
teins, which consist of G andG subunits (1). Agonist-occu-
pation ofGPCRs activates theG protein, leading to dissociation
of G fromG. G transmits GPCR signals via downstream
effectors such as phosphoinositide 3-kinase (PI3K) (2). PI3K
converts PI 4,5-bisphosphate (PIP2) to PI 4,5,3-trisphosphate
(PIP3), a second messenger, which recruits to the cell surface
and activates proteins containing a pleckstrin homology (PH)
domain (3, 4). Wortmannin is a fungal metabolite that acts as a
highly selective inhibitor of PI3K (5). The binding of LH or CG
to LHCGR results mainly in activation of Gs-coupled adenylyl
cyclase. The involvement of Gs-coupled adenylyl cyclase acti-
vation and subsequent cAMP accumulation in LHCGR-medi-
ated steroidogenesis is well established (6). It has been shown
that LH/CG-induced internalization and subsequent lysosomal
degradation of LHCGR is the most important contributor to
the down-regulation of this receptor (7).
Most GPCRs are internalized from the cell surface following
their activation to dampen the biological response, to recycle
and resensitize the receptor through dephosphorylation, or to
propagate signals through novel transduction pathways (8).
* This work was supported by BBSRC UK, MRC UK, and the Royal Society UK.
□S This article contains supplemental Figs. S1–S5.
1 To whom correspondence should be addressed: Institute of Life Science,
College of Medicine, Singleton Park, Swansea SA2 8PP, UK. Fax: 44-1792-
602147; E-mail: k.venkateswarlu@swansea.ac.uk.
2 The abbreviations used are: LHCGR, luteinizing hormone chorionic gonad-
otropin receptor; LH, luteinizing hormone; CG, chorionic gonadotropin;
GPCR, G-protein-coupled receptor; PI, phosphoinositide; PI3K, phosphoi-
nositide 3-kinase; PIP2, PI 4,5-bisphosphate; PIP, PI 3,4,5-trisphosphate; PH,
pleckstrin homology; PLC, phospholipase C; GRK, GPCR kinases; ARF, ADP-
ribosylation factor; GEF, guanine nucleotide exchange factor; GAP,
GTPase-activating protein; BFA, brefeldin A; GGA3, Golgi-associated, 
adaptin ear containing, ARF-binding protein 3; PBD, protein binding
domain; EPS15, EGFR pathway substrate clone 15; DN, dominant negative;
siRNA, small interfering RNA; DABCO, 1,4-diazabicyclo[2.2.2.]octane; Ro
201724, 4-(3-butuxy-4-methoxybenzyl) imidazolidi2-one; TE, Tris-EDTA;
PVDF, polyvinylidene fluoride; EGFR, epidermal growth factor receptor;
PBP10, PIP2-binding peptide; PIP5K, PI 4-phosphate 5-kinase.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 287, NO. 24, pp. 20443–20455, June 8, 2012
© 2012 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
JUNE 8, 2012•VOLUME 287•NUMBER 24 JOURNAL OF BIOLOGICAL CHEMISTRY 20443
 by Venkateswarlu Kanam
arlapudi, on June 8, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
http://www.jbc.org/content/suppl/2012/04/20/M112.362087.DC1.html 
Supplemental Material can be found at:
Agonist-inducedGPCR internalization is predominantlymedi-
ated by GPCR kinases (GRKs), arrestins, and clathrin-coated
pits. GRKs phosphorylate agonist-activated GPCRs to facilitate
the recruitment of arrestins, which target GPCR to clathrin-
coated pits for rapid internalization (9). Dynamin GTPases
plays a key role in agonist-induced GPCR internalization by
inducing the fission of clathrin-coated vesicles. However, in the
case of LHCGR, formation of the receptor/arrestin complex
depends mostly on the agonist-induced activation of the
LHCGR rather than on the phosphorylation of the LHCGR (10)
and the ARF6 small GTPase plays a critical role in the recruit-
ment of -arrestin (11). In the follicular membrane, the ago-
nist-stimulation of LHCGR results in ARF6 activation and
release of arrestins from the plasmamembrane,making it avail-
able for binding to LHCGR with subsequent internalization of
the receptor (11).
ARF6 is amember of theARF family of small GTPases, which
regulate multiple cellular events by cycling between active
GTP- and inactive GDP-bound forms. ARFs depend on gua-
nine nucleotide exchange factors (GEFs) for activation and
GTPase activating proteins (GAPs) for inactivation. Among the
six known mammalian ARF isoforms (ARFs1–6), ARF1 and
ARF6 are the best characterized. ARF1 localizes to and acts at
the Golgi whereas ARF6 localizes to and acts at the cell periph-
ery. ARF6 mediates cell surface receptor internalization and
reorganization of the actin cytoskeleton beneath the plasma
membrane (12). Brefeldin A (BFA), a fungal toxin, inhibits acti-
vation of ARFs1–5 but not ARF6 (13, 14). However, ARF6 acti-
vation by the cytohesin family of ARF GEFs is inhibited by
SecinH3, a cell permeable triazole compound (15).On the other
hand QS11 is a cell permeable purine derivative that can
increase endogenous ARF1-GTP and ARF6-GTP levels in cells
by inhibiting ARF GAP activity (16). There are four cytohesin
family members in humans (cytohesins 1–4), each of which
contain a PH domain that binds to PIP3. Cytohesins 1–3 trans-
locate from the cytoplasm to the plasma membrane in a PI3K-
dependent manner, where they activate ARF6 (6, 17–21).
It is well established that the agonist-induced internalization
of LHCGR and several other GPCRs requires ARF6-regulated
recruitment and/or activation of several proteins, implicating
ARF6 as the central regulator of receptor internalization (11,
22). However, the mechanisms by which ARF6 regulate ago-
nist-induced GPCR internalization remain incompletely
understood. Here we investigated the molecular details by
which ARF6 regulates agonist-induced HLHCGR internaliza-
tion using various pharmacological inhibitors and genetic
mutants. Our studies demonstrate the activation of ARF6 by
agonist-occupied HLHCGR through G, PI3K, and cytohesin
ARF GEFs, and the involvement of activated ARF6 in HCG-
induced HLHCGR internalization through PIP2, clathrin,
NM21-H1, and dynamin. In addition we demonstrate a direct
relationship between the expression of cell surface HLHCGR
and the extent of cAMP signaling.
MATERIALS ANDMETHODS
Antibodies and Other Reagents—Antibodies used in the
experiments were: mouse monoclonal anti-Myc clone 4A6
(Upstate Biotechnology), mouse monoclonal anti-ARF6 3A-1
(Santa Cruz Biotechnology), rabbit polyclonal anti-ARF1 (a gift
from Prof. Sylvain Bourgoin, Laval University, Quebec, Can-
ada), fluorophore-coupled secondary antibodies (Jackson
ImmunoResearch Lab), alkaline phosphatase-conjugated sec-
ondary antibody (Bio-Rad) and horseradish peroxidise (HRP)-
conjugated secondary antibodies (GE Healthcare). Phamaco-
logical inhibitors SecinH3 andQS11were obtained fromMerck
whereas Wortmannin, Gallein, and Dynasore were from Toc-
ris. Lipopectamine 2000 was from Invitrogen whereas mowiol
and PIP2-binding protein (PBP10)were fromMerck. Enhanced
chemiluminescence (ECL) advanced reagent was obtained
from GE Healthcare. All other reagents unless otherwise spec-
ified were obtained from Sigma-Aldrich.
Plasmids—The plasmid Myc-HLHCGR, which encodes the
full-length receptorwith an internalMyc tag, (inserted between
aa 72 and 73) at its N-terminal end described previously (10).
The plasmidNM23-H1 plasmidwas constructed by subcloning
NM23-H1 cDNA into pCMV-FLAG vector. NM23-H1 H118C
was generated by using QuickChange site-directed mutagene-
sis kit (Stratagene). GST-GGA3 protein binding domain (PBD)
and GFP-cytohesin 2 plasmids described previously (23–25).
EPS15 (EGFR pathway substrate clone 15) dominant negative
(DN) mutant excised from pEGFP plasmid by EcoRI digestion
and subcloned into the EcoRI site of pCMV-FLAG vector (26).
siRNA Oligonucleotides—The specific target nucleotide
sequences, 5-TGACAGAGAGCGTGTGAAC-3 for human
ARF1 siRNA and 5-GCACCGCATTATCAATGACCG-3 for
human ARF6 siRNA were described previously (27, 28). As a
control, an siRNA duplex consisting of a unique sequence that
does not have significant homology to any mammalian gene
sequences was used. The 21 nucleotide siRNA duplexes were
synthesized by Eurogentec.
Cell Culture and Transient Transfection—HEK 293 cells
were cultured in DMEM (serum-free medium (SFM)) supple-
mented with 10% fetal calf serum (FCS), 2 mM glutamine, 100
units/ml penicillin, and 0.1 mg/ml streptomycin at 37 °C in a
humidified atmosphere with 5% CO2. Cells were transfected
with indicated plasmids or siRNA or plasmids and siRNA using
Lipofectamine 2000™ according to the manufacturers’ instruc-
tions. Cellswere split, 1 day after transfection, into poly-L-lysine
(0.1mg/ml) coated 24-well plates (for ELISA and cAMPassays),
6-cm plates and onto poly-L-lysine (0.1 mg/ml) coated 13 mm
coverslips placed in wells of 24-well plate (immunofluores-
cence) used next day for experimentation.
Receptor InternalizationAssay—Internalization ofHLHCGR
was assessed by ELISA as previously described (24). Briefly,
HEK293 cells transiently transfected with Myc-tagged HLH-
CGRwere serum starved for 2 h and then incubated without or
with HCG 10 IU/ml for 30 min at 37 °C. Where indicated, cells
were incubated with the inhibitors for time mentioned in the
figure legends at 37 °C prior to stimulationwithHCG. The cells
were fixed with 3.7% (w/v) paraformaldehyde in TBS (10 mM
Tris-HCl, pH 7.5, 150 mM NaCl)) for 5 min, blocked with 1%
BSA for 45 min and incubated with an anti-Myc mouse mono-
clonal antibody for 1 h and alkaline phosphatase-conjugated
anti-mouse IgG for 1 h. Cells were then incubated with p-nitro-
phenylphosphate at 37 °C and read color change at 405 nm
using a microplate reader.
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Immunofluorescence—Intracellular distribution of cell sur-
face HLHCGR was assessed by immunofluorescence as
described (24). Briefly, cells serum starved and treated with
inhibitors as mentioned above were incubated with an anti-
Myc mouse monoclonal antibody for 1 h at 4 °C, stimulated
with HCG 10 IU/ml in presence or absence of the inhibitors at
37 °C for 30 min. The cells were fixed with 3.7% (w/v) parafor-
maldehyde for 30 min, permeabilized using 0.2% Triton X-100,
blocked with 1% BSA and then incubated with fluorescence-
tagged anti-mouse IgG for 1 h. The cells were mounted on
slides with mounting solution (0.1 M Tris-HCl, pH 8.5, 10%
mowiol, and 50% glycerol, containing 2.5% DABCO (1,4-
diazabicyclo[2.2.2.]octane), and immunofluorescent staining
was visualized using a Leica confocalmicroscopewith a 63 oil
immersion lens.
cAMPAssay—The cells were serum starved for 2 h and incu-
bated with 0.25 mM concentration of phosphodiesterase inhib-
itor Ro 201724 at 37 °C for 15 min. The cells were then stimu-
lated with HCG 10 IU/ml for 30 min 37 °C. Where indicated,
cells were incubated with the inhibitors for indicated time at
37 °C prior to stimulation with HCG. cAMP levels were then
determined as previously described (24).
ARF6 Activation Assay—ARF6 activation was assessed by
using theGST-GGA3PBD (amino acids 1–316) pulldown assay
as described previously (25). The GST-GGA3 PBD fusion pro-
tein purified and coupled to glutathione beads as described
(18). The transfected cells stimulated without or with HCG 10
IU/ml for 30 min at 37 °C in the presence of or absence of
inhibitor were lysed using ice-cold lysis buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, and 10 mM MgCl2) with 1% protease
inhibitors mix. The cell lysates were incubated with glutathi-
one-Sepharose beads coupled to 50 g of purified GST-GGA3
PBD fusion protein at 4 °C for 2 h. The beadswerewashed three
times with the wash buffer (50 mM Tris-HCl, pH 7.5, 10 mM
MgCl2, 150 mM NaCl, and 1% Triton X-100). The lysates that
not incubated with the beads were used as an input controls.
ARF6- or ARF1-GTP bound to the beads and total ARF1 or
ARF6 in the inputs were determined by immunoblotting using
an anti-ARF6 or an anti-ARF1 antibody. Immunoblots were
scanned and the GTP-bound ARF6 precipitated with GST-
GGA3 PBD beads was normalized to total ARF6 levels in the
lysates to compare ARF6-GTP levels in different conditions.
Immunoblotting—Proteins were separated by SDS-PAGE,
transferred onto PVDF membrane and immunoblotted using
primary antibody and the HRP-conjugated secondary antibody
as described previously (29).
Data Analysis—Image-J programwas used for densitometric
analysis. Data were analyzed by using the GraphPAD Prism
program. Unless indicated otherwise, results were expressed as
the mean  S.E. of three experiments. The confocal images
shown in the figures are representative of three different cell
preparations.
RESULTS
Involvement of ARF6 in the HCG-induced Internalization of
HCGLHR—We transiently transfected HEK293 cells with
HLHCGR containing an N-terminal Myc epitope tag (HEK-
HCGLHR cells) and first assessed by ELISA both the concen-
tration- and time-dependence of HCG-induced HLHCGR
internalization. When added to the cells for 30 min, HCG
induced receptor internalization with an EC50 of8 IU/ml and
amaximumof45% receptor internalization being observed at
100–1000 IU/ml of the agonist (supplemental Fig. S1A). Addi-
tion of 10 IU/ml of HCG to the cells led to time-dependent
internalization of HLHCGR (supplemental Fig. S1A) withmax-
imum HLHCGR internalization being observed 30–60 min
after agonist addition. Immunofluorescence of HEK-HCGLHR
cells confirmed the agonist-dependent internalization of HLH-
CGR. HCG caused a decrease in cell surface expression of
HLHCGR and concomitant increase in intracellular bright
punctuate spots, indicating internalization of the receptor (sup-
plemental Fig. S1B). We next assessed the concentration and
time dependence of agonist-induced cAMP production in
HEK-HCGLHR cells. The EC50 value for HCG-induced cAMP
accumulation was 5.1 IU/ml and a maximum 6-fold over basal
increase in cAMP accumulation being observed for HCG at
100–1000 IU/ml for 30 min and 10 IU/ml for 60 min (supple-
mental Fig. S1C). Unless otherwise indicated, a standard ago-
nist treatment of 10 IU/ml of HCG for 30 min was used in
further experiments.
To understand the role of ARF6 in HCG-induced internal-
ization of HCGLHR, we first analyzed the effect of down-regu-
lation of ARF6 and ARF1 on agonist-induced HLHCGR, using
previously validated ARF6 and ARF1 siRNAs (27, 28). The effi-
ciency of down-regulation of ARF6 and ARF1 protein expres-
sion in the cells transfected with ARF6 and ARF1 siRNAs,
respectively, is shown in Fig. 1A. ARF6 expression was signifi-
cantly depleted (80%) in the cells transfected with ARF6
siRNA but not in either ARF1 siRNA or universal negative con-
trol siRNA-treated cells. Similarly ARF1 expression was con-
siderably reduced (90%) in ARF1 siRNA treated but not in
ARF6 or negative control siRNA-transfected cells. Depletion of
ARF1 or ARF6 had no affect on cell surface expression of HLH-
CGR in unstimulated cells, as assessed by ELISA (data not
shown).However, depletion ofARF6but notARF1 significantly
inhibited HCG-induced HLHCGR internalization (10% cell
surface receptor loss in ARF6 siRNA-transfected cells com-
pared with 30% in control or ARF1 siRNA-transfected cells)
(Fig. 1B). This was further confirmed by immunofluorescence
analysis (Fig. 1C). Agonist-induced HLHCGR internalization,
as evident by punctuate staining in the cytosol, was markedly
reduced in cells transfected with ARF6 siRNA but not ARF1
siRNA.Next, we investigated the effect of ARF1 orARF6 deple-
tion on HCG-induced HLHCGR activation by measuring
cAMP accumulation (Fig. 1D). Basal cAMP levels (12.7  1.8
pmol of cAMP per mg protein) were not affected by depletion
of ARF1 (12.4  2.2 pmol of cAMP per mg protein) or ARF6
siRNA (13.1  1.2 pmol of cAMP per mg protein). However,
HCG-stimulated cAMP accumulation was greater (8.3  0.5-
fold over basal) in ARF6 siRNA- transfected HEK-HLHCGR
cells but not ARF1 siRNA (3.5 0.2-fold over basal) or control
siRNA (3.4  0.3-fold over basal) transfected cells. These
results confirm the role of ARF6 in agonist-induced HLHCGR
internalization and signaling.
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The N-myristoylated ARF1 (Myr-ARF1; composed of
2–17aa of ARF1) and ARF6 (Myr-ARF6; consists of 2–13 aa of
ARF6) peptides have previously been shown to inhibit the func-
tions of ARF1 and ARF6, respectively (27, 30). We synthesized
the Myr-ARF1 and Myr-ARF6 peptides and made them mem-
brane permeable by coupling them to the cell-permeating
domain of the Drosophila antennapedia protein (penetratin).
The membrane permeable Myr-ARF1 andMyr-ARF6 peptides
were used to determine the specificity of ARF6 involvement in
HCG-induced HLHCGR internalization in intact cells (31, 32).
Treatment of HEK-HLHCGR cells with theMyr-ARF6 peptide
but not the Myr-ARF1 peptide or control peptide penetratin
inhibited HCG-induced HLHCGR internalization in a concen-
tration-dependent manner with an EC50 of 0.5  0.1 M (Fig.
2A). This inhibitory effect of the Myr-ARF6 peptide was con-
firmed by immunofluorescence (Fig. 2B), whereMyr-ARF6 but
not Myr-ARF1 or control penetratin blocked HCG-induced
internalization of HLHCGR. Furthermore, HCG-induced
cAMPaccumulationwas significantly increased from3.4 0.4-
fold to a maximum of8.5 1.7-fold, as the concentration of
the ARF6 peptide was increased, with an EC50 of 0.5 0.2 M,
whereas the ARF1 peptide and penetratin treatment had no
effect on HCG-induced cAMP accumulation (Fig. 2C).
ARF6 Activation by HCG Stimulation of HEK-HCGLHR
Cells—WhenARF6 is in its active GTP-bound form, it presum-
ably interacts with downstream effectors in the HLHCGR sig-
naling pathway to promote agonist-induced receptor internal-
ization (11). We used the GST-GGA3 PBD pulldown assay to
assess if HCG-stimulation of HEK-HCGLHR cells causes ARF6
activation. The GST-GGA3 PBD specifically binds to the GTP-
bound form of ARF and therefore the fusion protein coupled to
glutathione beads along with an ARF1- or ARF6-specific anti-
body has been used to detect activated endogenous ARF1 or
ARF6 in cell lysates (23). Upon stimulationwithHCG, the levels
of endogenousARF6-GTP, but notARF1-GTP, are increased in
HEK-HLHCGR cells (Fig. 3A), indicating that HCG-stimulated
HLHCGR selectively activates ARF6 in these cells. We next
assessed the concentration- and time-dependent activation of
ARF6 in HCG-stimulated HEK-HCGLHR cells (Fig. 3, B and
C). When HCG was added to the HEK-HCGLHR cells for 30
min,ARF6was activatedwith increasing concentration ofHCG
and reached saturation at 100 IU/ml (3.1 0.9-fold over basal).
Addition of 10 IU/ml ofHCG to the cells led to the time-depen-
dent activation of ARF6withmaximumARF6 activation (4.1
0.1-fold over basal) being observed 30–60 min after agonist
addition. The kinetics of HCG-induced ARF6 activation corre-
FIGURE 1. Effect of ARF1 and ARF6 siRNA on HCG-induced HLHCGR internalization and cAMP accumulation. A, immunoblot analysis of the lysates of
HEK293 cells co-transfected with HLHCGR (HEK-HLHCGR cells) and 100 nM of control siRNA, ARF1 siRNA, ARF6 siRNA, or nothing, using an anti-ARF1 rabbit
polyclonal antibody (pAb), an anti-ARF6 mouse monoclonal antibody (mAb), or an anti--tubulin mouse mAb. ARF1 pAb and ARF6 mAb confirm the
siRNA-induced down-regulation of ARF1 and ARF6, respectively, while -tubulinmAbwas used as a loading control. B, HEK-HLHCGR cells co-transfectedwith
control siRNA, ARF1 siRNA, ARF6 siRNA, or nothing were stimulated with 10 IU/ml HCG for 30 min at 37 °C. The cell surface expression of HLHCGR was
determined by ELISA. C, immunofluorescence analysis of the effect of ARF1 or ARF6 down-regulation on HCG-induced HLHCGR internalization. HEK-HLHCGR
cells co-transfectedwithorwithout control siRNA,ARF1 siRNA, orARF6 siRNAwere incubatedwith an anti-Myc antibody at 4 °C for 1h followingwhich the cells
were incubated in the presence or absence of 10 IU/ml HCG at 37 °C for 30 min. After fixing, the cells were permeabilized, and immunostained using
TRITC-conjugated anti-mouse IgG secondary antibody, and the staining visualized by confocal microscopy. D, cAMP accumulation in HCG-stimulated (10
IU/ml, 30 min) HEK-HLHCGR cells co-transfected without or with control siRNA, ARF1 siRNA, or ARF6 siRNA.
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late with those of HCG-stimulated receptor internalization
(supplemental Fig. S1A). Furthermore, ARF6 activation in
HCG-stimulated HEK-HLHCGR cells was specifically inhib-
ited by theMyr-ARF6 peptide but not theMyr-ARF1 or control
penetratin peptide (Fig. 3D). These data suggest a critical role
for ARF6 activation in the internalization of HLHCGR.
Effect of SecinH3 and QS11 on HCG-stimulated HLHCGR
Internalization and cAMP Production—We next used inhibi-
tors of ARF GEFs (SecinH3 and BFA) and an inhibitor of ARF
GAP (QS11) to further analyze the effect of ARF6 activation on
HCG-induced HLHCGR internalization. SecinH3 prevents the
activation of ARF6 by inhibiting the function of the cytohesin
family of ARF GEFs whereas ARF6 activation is insensitive to
BFA, which instead inhibits the activation of other members of
the ARF family (15, 33). QS11 is a broad spectrum ARF GAP
inhibitor that preventsARF6 inactivation (16). SinceARF6 acti-
vation is required for HLHCGR internalization, we hypothe-
sized that SecinH3 may decrease and QS11 may increase
HCG-induced HLHCGR internalization. Accordingly, HEK-
HLHCGR cells were pretreated with or without inhibitor and
then analyzed for HCG-induced HLHCGR internalization (by
ELISA and immunofluorescence) and cAMP accumulation.
SecinH3 inhibitedHCG-inducedHLHCGR internalization in a
concentration-dependent manner, with a maximum decrease
of internalization (95.5  0.9%) at a concentration of 60 M
(Fig. 4A). BFA did not inhibit HCG-induced HLHCGR inter-
nalization even at a concentration (50 g/ml) that is known to
exert a maximal inhibitory effect on ARF1 function (supple-
mental Fig. S2A). Unlike SecinH3, QS11 caused a concentra-
tion-dependent increase inHCG-induced receptor internaliza-
tion, with a maximum increase of the internalization (48.9 
0.8%) at a concentration of 12.5 M (supplemental Fig. S2A).
These findings were confirmed through visualization of the
intracellular distribution of receptor, in response to HCG stim-
ulation (Fig. 4B and supplemental Fig. S2B). Upon stimulation
with HCG, HLHCGR internalization, as determined by the
receptor’s intracellular redistribution, wasmarkedly reduced in
SecinH3-treated cells but increased in QS11-treated cells as
compared with that in control DMSO- or BFA-treated cells.
SecinH3 increased HCG-induced cAMP accumulation in a
concentration-dependent manner with a maximum effect
(11.2  0.8-fold over basal) being observed at a concentration
of 30 M HCG (Fig. 4C). This demonstrates the prolongation
of HCG-stimulated HLHCGR signaling due to inhibition of
receptor internalization by SecinH3 treatment. BFA did not
affect cAMP accumulation inHCG-stimulatedHEK-HLHCGR
cells (supplemental Fig. S2C). QS11-treated cells had slightly
lower levels of cAMP accumulation in HCG-stimulated cells
(3.8 0.4-fold over basal) (supplemental Fig. S2C).
Effect ofWortmannin (PI3K inhibitor) andGallein ( Inhib-
itor) on HCG-induced HLHCGR Internalization and cAMP
Accumulation—The above experiments have established a role
for ARF6 activation in HLHCGR internalization and the time
scale of signaling. ARF6 activation involves the recruitment of
its GEFs such as cytohesins to the plasma membrane via their
binding to PIP3 (19). PIP3 is the lipid second messenger pro-
duced by PI3K in agonist-stimulated cells (34). PI3K can be
activated directly or through GRK2 by G subunits that dis-
FIGURE 2. Effect of the MyrARF6 and MyrARF1 inhibitory peptides on HCG-stimulated HLHCGR internalization and cAMP accumulation. A, HEK-
HLHCGRcellswere incubatedwith 0.1–5Mpenetratin (f), penetratin-coupledMyr-ARF1 (●) or penetratin-coupledMyr-ARF6 (Œ) peptides for 2h at 37 °C and
then incubated in the presence or absence of 10 IU/ml HCG for 30 min. HLHCGR internalization was determined by ELISA. B, immunofluorescence analysis
showing the HCG-induced (10 IU/ml HCG, 30 min) internalization of HLHCGR cells in the absence or presence of 2.5 M penetratin or penetratin coupled
Myr-ARF1 or Myr-ARF6 peptides. C, cAMP accumulation in HCG-stimulated (10 IU/ml HCG, 30 min) HEK-HLHCGR cells in the presence of 0.1–5 M penetratin,
penetratin-coupled Myr-ARF1, or penetratin-coupled Myr-ARF6 peptides.
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sociate fromG subunit upon agonist binding to theGPCR (35,
36). Wortmannin is a potent inhibitor (IC50 10 nM) of PI3K
(37). Gallein efficiently blocks the effects of G subunits and
has a relatively high affinity for interaction with G (Kd400
nM); it disrupts the interactions of Gwith downstream bind-
ing partners such as PI3K and GRK2 (38, 39).
We therefore studied the effect of Wortmannin and Gallein
onHCG-stimulatedHLHCGR internalization and cAMP accu-
mulation. Wortmannin concentration-dependently inhibited
HCG-induced internalization of HLHCGR from 34.1  1.8%
internalization to 13.1  0.9% internalization at 100 nM of the
inhibitor (Fig. 4A). Gallein treatment also resulted in a concen-
tration-dependent inhibition of agonist-induced receptor
internalization from 30.7 1.3% to 15.7 1.3% as the concen-
tration of Gallein increased from 0.4 to 10 M (Fig. 4A). These
results demonstrate a direct role for G-activated PI3K in the
HCG-induced HLHCGR internalization. These observations
were supported by immunofluorescence studies, which dem-
onstrated the inhibition of HCG-induced HLHCGR internal-
ization byWortmannin and Gallein (Fig. 4B). We then investi-
gated the effects of Wortmannin and Gallein on HCG-induced
cAMP accumulation. Both Wortmannin and Gallein caused a
concentration-dependent increase in HCG-stimulated cAMP
accumulation (Fig. 4C).
Effect of SecinH3, QS11, Wortmannin, and Gallein on ARF6
Activation by HCG in HEK-HLHCGRCells—We next analyzed
the effect of SecinH3, QS11,Wortmannin andGallein onARF6
activation to determine whether these inhibitors might affect
HCG-induced HLHCGR internalization via regulation of
ARF6. For this purpose, we determined HCG-induced ARF6
activation in HEK-HLHCGR cells pretreated with or without
each inhibitor. HCG-stimulated ARF6 activation in HEK-HL-
HCGR cells pretreated with either BFA or vehicle DMSO was
the same as that in untreated cells, as shown by the intensity of
the ARF6-GTP bands (Fig. 5A). However, SecinH3 inhibited
HCG-induced ARF6 activation in HEK-HLHCGR cells in a
concentration-dependent manner (Fig. 5A). In contrast, QS11
increased ARF6-GTP levels in a concentration-dependent
manner in HCG-stimulated HEK-HLHCGR cells (supplemen-
tal Fig. S3). The HCG-induced ARF6 activation in HEK-HLH-
CGR cells was inhibited by Wortmannin and Gallein in a con-
centration-dependent manner (Fig. 5, B and C). Together with
the results of Fig. 4 and supplemental Figs. S2 and S3, these
results indicate that pharmacological inhibition of HCG-in-
duced ARF6 activation reduces agonist-induced HLHCGR
internalization.
Effect of SecinH3, Wortmannin, and Gallein on Cytohesin 2
Translocation and HLHCGR Internalization in HCG-stimu-
FIGURE 3. HCG stimulation of HLHCGR induces ARF6 but not ARF1 activation in HEK-HLHCGR cells. A, HEK 293 cells transfected with either pcDNA3 or
Myc-HLHCGR were serum starved and treated with or without 10 IU/ml HCG for 30 min at 37 °C. The cells were lysed, and the cell lysates incubated with
GST-GGA3 PBD resin to analyze the levels of endogenous ARF1-GTP and ARF6-GTP. Total ARF1 or ARF6 expression in the cell lysates as well as the active ARF1
and ARF6 bound to the resin were detected by immunoblotting using anti-ARF1 rabbit pAb and anti-ARF6 mouse mAb, respectively. B and C, analysis of
concentration- (B) and time-dependent (C) increase in ARF6 activation in HCG-stimulated HEK-HLHCGR cells. HEK-HLHCGR cells stimulated without or with
1–1000 IU/ml HCG for 30min or 10 IU/ml HCG for up to 60minwere lysed and subjected toGST-GGA3 PBDpulldown. Total ARF6 andARF6-GTPwere detected
by immunoblotting using an anti-ARF6 mouse mAb. Densitometric analysis of the ARF6-GTP is shown as a histogram, after normalizing to the expression of
total ARF6 present in the sample. D, effect of the Myr-ARF6 inhibitory peptide on ARF6 activation in HCG-stimulated HEK-HLHCGR cells. HEK-HLHCGR cells
preincubated for 2 h at 37 °C without (first lane) or with 2.5 M penetratin (second lane) or penetratin coupled Myr-ARF1 (third lane) or Myr-ARF6 (fourth lane)
peptides were subsequently stimulated with 10 IU/ml HCG for 30 min, lysed and subjected to GST-GGA3 PBD pulldown to quantify endogenous ARF6-GTP.
ARF6-GTP and total ARF6 levels were each assessed by immunoblotting. Densitometric analysis of ARF6-GTP is shown as a histogram, after normalizing to the
expression of total ARF6 present in the sample.
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lated HEK-HLHCGR Cells—We have previously shown the
PI3K-dependent translocation of cytohesins 1–3 from the cyto-
sol to the plasmamembrane, where they activate ARF6 (18–21,
40). By activating ARF6 at the plasma membrane, cytohesin 2
can regulate the internalization of LHCGR (11). We have now
shown that SecinH3, Wortmannin, and Gallein affect HCG-
induced HLHCGR internalization by inhibiting ARF6 activa-
tion. Since Wortmannin and Gallein do not inhibit ARF6 acti-
vation directly, we hypothesized that these inhibitors affect
ARF6 activation by inhibiting cytohesin translocation. To test
this hypothesis, we analyzed the effect of Wortmannin or Gal-
lein pretreatment on the cellular distribution of GFP-tagged
cytohesin 2 in HCG-stimulated HEK-HLHCGR cells. For this
purpose, we co-transfected HEK 293 cells with Myc-HLHCGR
and either a GFP or GFP-cytohesin 2 plasmid and subsequently
analyzed HCG-induced HLHCGR internalization. HCG-in-
duced HLHCGR internalization was slightly higher (40%) in
the GFP-cytohesin 2 expressing HEK-HLHCGR cells than that
in control cells expressing either the receptor alone or the
receptor with GFP (each 31%) (data not shown). We then
analyzed the localization ofGFP-cytohesin 2 inHEK-HLHCGR
cells stimulated with and without HCG. As we observed previ-
ously (21), GFP-cytohesin 2 localized to the cytosol in the
unstimulated HEK-HLHCGR cells whereas HCG-stimulation
induced the translocation of GFP-cytohesin 2 to the plasma
membrane and the internalization of the surface HLHCGR to
the cytoplasm (Fig. 6). Wortmannin and Gallein inhibited
HCG-inducedHLHCGR internalization aswell asGFP-cytohe-
sin 2 translocation, whereas SecinH3 inhibited HCG-induced
HLHCGR internalization but not cytohesin 2 translocation.
These results suggests that the inhibition of LHCGR internal-
ization byWortmannin andGallein is via the inhibition of cyto-
hesin 2 translocation to the plasma membrane, and that due to
SecinH3 through a reduction in cytohesin 2-mediated ARF6
activation.
Effect of NM23-H1 and EPS15 DN Mutants, Dynasore, and
PBP10 on HLHCGR Internalization and cAMP Accumulation
in HCG-stimulated HEK-HLHCGR Cells—It has been shown
previously that LHCGR internalization occurs via a clathrin-
and dynamin-dependent process (6, 41). The clathrin complex
mediates LHCGR internalization whereas dynamin GTPase
causes the fission of clathrin-coated vesicles (10). ARF6 pro-
motes clathrin-mediated internalization by recruiting NM23-
H1 and/or the adaptor protein AP2 in polarized cells such as
FIGURE 4. Effect of SecinH3 (ARF GEF inhibitor), Wortmannin (PI3K inhibitor), and Gallein (G inhibitor) on HCG-induced HLHCGR internalization
and cAMP accumulation. A, HEK-HLHCGR cells pre-incubated with either SecinH3 (1–60M,E,●), Wortmannin (0.001–1M,f,) or Gallein (0.4–50M,,
Œ) for 15min (wortmannin andGallein) or 2 h (SecinH3) at 37 °Cwere incubatedwithout (open symbols) orwith (solid symbols) 10 IU/ml HCG for 30min at 37 °C
and receptor internalization determined by ELISA. B, immunofluorescence analysis of the effect of SecinH3, Wortmannin and Gallein on HCG-stimulated (10
IU/ml HCG, 30 min) HLHCGR internalization. C, cAMP accumulation in unstimulated (open symbols) or HCG-stimulated (solid symbols; 10 IU/ml HCG, 30 min)
HEK-HLHCGR cells pretreated with the indicated concentrations of SecinH3, Wortmannin, or Gallein as described in part A above.
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neurons and epithelial cells (42). NM23-H1 is a nucleoside
diphosphate kinasewhich activates dynamin-dependent fission
of clathrin coated endocytotic vesicles (43). ARF6-GTPbinds to
and activates PI 4-phosphate 5-kinase (PIP5K), leading to a
large increase in PIP2 at the cell surface (44). ARF6-GTP and
PIP2 function synergistically to recruit AP-2, suggesting a role
for ARF6 in clathrin-coated pit assembly (44, 45). Although
ARF6 activation has been linked to the dissociation of arrestin
to facilitate LHCGR internalization, a possible direct involve-
ment of ARF6 in clathrin-mediated LHCGR internalization has
not been evaluated (11). We hypothesized that ARF6 may reg-
ulate HLHCGR internalization by recruiting NM23-H1 to the
clathrin-coated pits leading to PIP5K activation. To deter-
mine the involvement of this pathway, we assessed the effect of
the DN mutants of NM23-H1 (NM23-H1H118C, kinase defec-
tive) and EPS15 (EPS1595–295) on HCG-induced HLHCGR
internalization (by ELISA and immunofluorescence) and
cAMP accumulation, cytohesin 2 translocation and ARF6 acti-
vation (26, 43). EPS15, one of the components of the clathrin
complex andAP2 interactor, is required for clathrin-dependent
endocytosis. Using the same approaches, we also assessed the
effect of a cell permeable PBP10 (a decapeptide derived from
the PIP2-binding region in segment-2 of gelsolin) and a chem-
ical inhibitor of dynamin (Dynasore) on HCG-induced HLH-
CGR internalization (46, 47).
Dynasore and PBP10 inhibited HCG-induced HLHCGR
internalization in a concentration-dependent manner (supple-
mental Figs. S4A and S5A). The cells treated with Dynasore
showed a decrease in HCG-induced internalization from
34.0 1.8% to 9.7 1.2% at 80MDynasore (supplemental Fig.
S4A). PBP10 treatment also resulted in the inhibition of recep-
tor internalization from 28.2 4.0% down to 4.8 2.2% at 10
M PBP10 (supplemental Fig. S5A). These observations were
supported by immunofluorescence studies, in which inhibition
of HCG-induced HLHCGR internalization by Dynasore and
PBP10 was evident (supplemental Figs. S4B and S5B). Consist-
ent with the internalization results, both Dynasore and PBP10
caused a concentration-dependent increase in levels of HCG-
stimulated cAMP accumulation in HEK-HLHCGR cells
(supplemental Figs. S4C and S5C). A significant decrease in
HLHCGR internalization and a concomitant increase in HLH-
CGR-mediated cAMP accumulation was observed in HCG-
stimulated HEK-HLHCGR cells co-transfected with either
NM23-H1 or EPS15 DNmutants, but not NM23-H1WT (Figs.
7, A–C and 8, A–C). Approximately 12% of the cell surface
receptor expressionwas lost inNM23-H1 or EPS15DNmutant
plasmid-expressing cells compared with 30% in control
empty plasmid or NM23-H1 WT construct-expressing cells
(Figs. 7A and 8A). This was further confirmed by immunofluo-
rescence analysis (Figs. 7B and 8B). The agonist-induced HLH-
CGR internalization, as evident by punctuate staining in the
cytosol, was markedly reduced in cells expressing NM23-H1 or
EPS15 DN mutant plasmids but not control empty vector or
NM23-H1 WT plasmid. Next, we investigated the effects of
NM23-H1 and EPS15 mutants on HCG-induced HLHCGR
activation bymeasuring cAMP accumulation (Figs. 7C and 8C).
HCG-stimulated cAMP accumulation was increased in cells
expressingNM23-H1 or EPS15DNmutants but not NM23-H1
WT or control plasmid expressing HEK-HLHCGR cells. HCG-
induced cAMP levels in the cells exogenously expressing
FIGURE 5. Effect of SecinH3,Wortmannin andGallein onARF6 activation in HCG-stimulatedHEK-HLHCGR cells.HCG-stimulated (10 IU/ml HCG, 30min)
ARF6 activation was assessed by a GST-GGA3 PBD pulldown assay in HEK-HLHCGR cells preincubated with the indicated concentrations of (A) SecinH3, (B)
Wortmannin, or (C) Gallein. Total ARF6 levels in the cell lysate and the resin boundARF6-GTPwere visualized by immunoblot analysis with an anti-ARF6mouse
mAb.Densitometric analysis of ARF6-GTP is shownas a histogramafter normalizing to the expressionof total ARF6present in the sample. ForWortmannin and
Gallein, the effect of the drug vehicle (0.5%DMSO) on ARF6-GTP levels, was also determined. Solid bars indicatemeasurements made in the presence of HCG.
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NM23-H1WTwere similar to that of the cells transfected with
control plasmid.However, the agonist-induced cAMPaccumu-
lation was significantly greater in NM23-H1 or EPS15 DN
mutant expressing cells. Dynasore, PBP10, NM23-H1 DN, and
EPS15 DN had no effect on HCG-stimulated ARF6 activation
(Figs. 7D and 8D and supplemental Figs. S4D and S5D) or cyto-
hesin 2 translocation in the HEK-HLHCGR cells (Fig. 6). These
results indicate that dynamin, PIP2, NM23-H1, and clathrin
regulate HLHCGR internalization by acting downstream of
ARF6.
DISCUSSION
An important aspect of LHCGR activity and its regulation is
the internalization of agonist-activated receptors into the intra-
cellular compartments of the cell (48). ARF6 regulates the inter-
nalization of LHCGR as well as that of other GPCRs (11, 22),
however, themolecular mechanisms underlying ARF6 involve-
ment in GPCR trafficking are not well understood. In this study
we systematically dissected the molecular and cellular mecha-
nisms underlyingARF6 involvement in LHCGR internalization
(see summary in Fig. 9). In addition we suggest that the molec-
ular pathways identified here are likely to be shared by other
GPCRs where internalization is ARF6-dependent.
The down-regulation of ARF6 expression by siRNA or inhi-
bition of ARF6 by the Myr-ARF6 inhibitory peptide inhibited
the agonist-induced internalization of HLHCGR and produced
a corresponding increase in agonist-induced cAMP accumula-
tion in HCG-stimulated cells. Similarly, other studies have
shown that ARF6 down-regulation inhibits agonist-induced
internalization of GPCRs including the 2-adrenoreceptor
(2-AR), M2 muscarinic acetylcholine receptor and the angio-
tensin II type 1 (AT1) receptor (49), (50, 51). The inhibition of
receptor internalization following ARF6 down-regulation
causes the receptors to be retained for an increased period on
the cell surface, and thus prolongs adenylyl cyclase activation
with consequent increases in cellular cAMP accumulation.
These results confirm that ARF6 has a crucial role in agonist-
induced internalization of HLHCGR, which in turn determines
the dynamics of cellular signaling for this receptor.
ARF6 functions by cycling between the inactive GDP- and
active GTP-bound conformations, a process which is regulated
by GEF and GAP. The active form of ARF6, ARF6-GTP, inter-
acts with downstream effectors in the LHCGR signaling path-
way to promote receptor internalization. In this study ARF6
activation byHCG-stimulatedHLHCGRwas determined using
a GST-GGA3 PBD pulldown assay (23, 25, 52). HCG-stimula-
tion ofHLHCGR increased cellular levels of ARF6-GTP but not
ARF1-GTP, while the Myr-ARF6 peptide but not Myr-ARF1
peptide inhibited HCG-stimulated ARF6 activation. Together
these results indicate that HLHCGR specifically activates
ARF6, and further implicate ARF6-GTP as a central player in
HCG-inducedHLHCGR trafficking. FurthermoreARF6 is acti-
vated upon agonist-stimulation of other GPCRs including the
2-AR, as well as the follicle-stimulating hormone, M3musca-
rinic acetylcholine, fMet-Leu-Phe, H2 histamine, B2 brady-
kinin, andAT1 receptors (11, 49), suggesting that ARF6-GTP is
a central player in the trafficking of many GPCRs.
The cytohesin family of proteins act as GEFs for both ARF1
and ARF6 (53, 17). Although cytohesin 2 is thought to be
involved in porcine LHCGR desensitization (11), it is not
known whether cytohesin 2 is the ARF GEF responsible for
ARF6 activation downstream of LHCGR. In the present study
SecinH3, an inhibitor of ARF6 activation by cytohesins, mark-
edly inhibited the agonist-induced internalization of HLHCGR
while BFA, an inhibitor of ARFs 1–5 activation, had no such
effect. These data indicate that the activation of ARF6 by the
cytohesin family of ARF GEFs is a crucial step in HCG-stimu-
lated HLHCGR internalization. Cytohesin 2 is present in follic-
ular membranes at a relatively high concentration and there-
fore it is possible that cytohesin 2 mediates ARF6 activation
downstreamof LHCGR in that tissue (54). TheARFGAP inhib-
itor, QS11, increased HCG-induced receptor internalization
presumably by increasing levels of ARF6-GTP. In the cAMP
assay, SecinH3 treatment increased while QS11 decreased
HCG-stimulated cAMP production, indicating that the length
of time that the HLHCGR resides on the cell surface directly
determines the ability of this receptor tomediate signaling viaG
protein. Furthermore, HCG-induced ARF6 activation in HEK-
HLHCGR cells was reduced by SecinH3 and moderately
increased by QS11. We have previously demonstrated the
involvement of the ARF6 GAP centaurin-1 in 2-adrenore-
ceptor internalization (24). Centaurin-1 is likely to play a vital
role inGPCR trafficking bymodulating the activity ofARF6 (23,
FIGURE 6. Effect of various inhibitors on cytohesin 2 translocation and
HLHCGR internalization in HCG-stimulated HEK-HLHCGR cells. Immuno-
fluorescence analysis of GFP-cytohesin 2 translocation and receptor internal-
ization in HCG-stimulated (10 IU/ml HCG, 30 min) HEK-HLHCGR cells pre-
treated for 15 min (Wortmannin, Gallein, and Dynasore) or 2 h (SecinH3) at
37 °Cwithout or with the indicated inhibitor or co-transfectedwith EP15(DN)
or NM23-H1 (DN) plasmid. Red indicates anti-Myc antibody staining of Myc-
HLHCGR, green indicates GFP, and yellow indicates overlay of red and green.
Note that HCG-induced receptor internalization was inhibited by all drug
treatments and co-transfectionwith the indicatedDNplasmid,whereasHCG-
induced GFP-cytohesin 2 translocation was inhibited by Gallein and Wort-
mannin, but not by SecinH3, Dynasore, EPS15 DN, NM23-H1 DN, and PBP10.
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24), and our present results support the idea that the ARF6
activation by cytohesinARFGEFs is required forHCG-induced
HLHCGR internalization.
Our previous studies implicated PI3K inARF6 activation (19,
20). Consistent with this view, Wortmannin (PI3K inhibitor)
reduced HCG-stimulated HLHCGR internalization. These
results are similar to those obtained in HEK293 cells exoge-
nously expressing the 2-AR where inhibition of PI3K activity
with Wortmannin caused a dramatic decrease in receptor
internalization (36). Gallein, a G inhibitor, also reduced
HCG-stimulated HLHCGR internalization and was shown to
inhibit G-dependent PI3K-regulated chemokine receptor
activity (38, 39). The PI3K isoform is activated by G, and
therefore it is possible that this isoform of PI3K is involved in
the receptor internalization (55).Wortmannin andGallein also
reduced ARF6 activation in HEK-HLHCGR cells stimulated
with HCG, which correlated with the inhibition of receptor
internalization by these agents and suggesting thatG-depen-
dent PI3K-activation occurs upstreamofARF6 activation in the
HLHCGR trafficking pathway.
Cytohesins 1–3 translocate from cytosol to the plasmamem-
brane in a PI3K-dependent manner, where they activate ARF6
(20, 21, 53). Since agonist binding to HLHCGR results in ARF6
activation, we assessed whether cytohesin 2 translocates to the
plasma membrane in HCG-stimulated HEK-HLHCGR cells.
Cytohesin 2 translocated in those cells stimulated with HCG,
and the translocation was blocked byWortmannin and Gallein
but not by SecinH3. Cytohesin 2 translocates to the plasma
membrane by binding via its PH domain to PIP3, which is pro-
duced by PI3K (20). Wortmannin and Gallein will inhibit PI3K
activation whereas SecinH3 only inhibits cytohesin 2 GEF
activity. Therefore the former two inhibitors would be pre-
dicted to inhibit cytohesin 2 translocation whereas SecinH3
would not, as was the case. Our studies indicate thatWortman-
nin and Gallein inhibit HCG-induced internalization by block-
ing cytohesin translocationwhereas SecinH3 reduced the inter-
nalization by inhibiting cytohesin ARF GEF activity. Since
cytohesins translocate before activatingARF6, we can conclude
that G and PI3K act upstream of ARF6 activation by cyto-
hesin(s) in the ARF6 signaling pathway associated with HLH-
CGR internalization.
HLHCGR undergoes clathrin- and dynamin-mediated inter-
nalization in HCG-stimulated cells. EPS15 was first identified
as a substrate of EGFR kinase (56), but was subsequently found
to participate in clathrin-mediated endocytosis through inter-
action with the clathrin adaptor protein AP2, and could medi-
ate clathrin-coated pit formation (57). The DN mutant of
EPS15 decreased HLHCGR internalization and in addition
led to increased agonist-stimulated cAMP production. The
dynamin inhibitor, Dynasore, also decreased HCG-induced
HLHCGR internalization. This finding was similar to the
observation of Macia et al. (46), where transferrin receptor
FIGURE 7. Effect of NM23-H1DNmutant onHLHCGR internalization and cAMPproduction in HCG-stimulatedHEK-HLHCGR cells. A, HEK-HLHCGR cells
coexpressingWT or DNmutant NM23-H1were assayed by ELISA for surface HLHCGR receptor both in the absence and the presence of HCG (10 IU/ml, 30min).
In HCG-treated cells, NM23-H1 DN mutant inhibited HCG-induced receptor internalization. B, immunofluorescence analysis showing the inhibition of HCG-
stimulated (10 IU/ml HCG, 30 min) HLHCGR redistribution by coexpression of NM23-H1 DN mutant. C, cAMP production was increased in HCG-stimulated
HEK-HLHCGR cells expressing NM23-H1 DNmutant as comparedwith cells expressing either NM23-H1WT or control empty vector.D, using a GST-GGA3 PBD
pulldown assay, the levels of endogenous ARF6-GTP under basal conditions and in the presence of HCG (10 IU/ml, 30min) were not affected by coexpression
of NM23-H1 WT or NM23-H1 DN mutant. Total ARF6 and ARF6-GTP were visualized by immunoblot analysis with an anti-ARF6 mouse mAb. Densitometric
analysis of ARF6-GTP is displayed as a histogram after normalizing to the expression of total ARF6 present in each sample.
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trafficking was inhibited by Dynasore treatment of HeLa cells.
NM23-H1 plays an important role in endocytosis by providing
the GTP required for dynamin-dependent fission of coated
vesicles (43, 58). The NM23-H1 DN mutant inhibited agonist-
induced HLHCGR internalization and increased cAMP pro-
duction, indicating that NM23-H1 is important for HCG-stim-
ulated HLHCGR internalization. The ARF6-GTP activates
PIP5K, leading to a large increase in PIP2 at the cell surface (44,
45). PIP2 then recruits AP-2 to clathrin-coated pits, suggesting
a role for ARF6-GTP in clathrin-mediated endocytosis. PBP10,
amembrane permeable PIP2 binding peptide, inhibits clathrin-
mediated endocytosis by preventing AP2 binding to PIP2.
PBP10 decreased HCG-induced LHCGR internalization with a
concomitant increase in cAMP accumulation. Therefore from
the results obtained using Dynasore, PBP10, NM23-H1 DN,
and EPS15 DN, we can conclude that HCG-induced HLHCGR
internalization occurs through the clathrin/dynamin-depen-
dent pathway. However, none of these agents interfered with
HCG-stimulated ARF6 activation, suggesting importantly that
ARF6 is functioning upstream of these proteins in vivo.
In conclusion we find that ARF6 activation and HCG-in-
duced HLHCGR internalization are inhibited by Gallein (G
inhibitor), Wortmannin (PI3-K inhibitor), SecinH3 (cytohesin
ARF GEF inhibitor), the ARF6 inhibitory peptide, and
siRNA-mediated down-regulation of ARF6, but not by QS11
FIGURE8.Effect of EPS15DNmutantonHCG-inducedHLHCGR internalizationand cAMPaccumulation.A, HEK-HLHCGR cells coexpressing empty vector
or EPS15 DN plasmid were assayed by ELISA for surface receptor levels both in the absence and in the presence of HCG (10 IU/ml, 30 min). The EPS15 DN
construct decreased HCG-induced HLHCGR as compared with cells that were not transfected or were transfected with empty control vector. B, immunofluo-
rescence analysis showing the inhibition of HCG-stimulated (10 IU/ml HCG, 30 min) HLHCGR redistribution by coexpression of EPS15 DN mutant. C, cAMP
production was increased in HCG-stimulated HEK-HLHCGR cells expressing EPS15 DN mutant as compared with cells expressing either not transfected or
transfected with empty vector. D, using a GST-GGA3 PBD pulldown assay, the levels of endogenous ARF6-GTP under basal conditions and in the presence of
HCG (10 IU/ml, 30 min) were not affected by coexpression of EPS15 DN mutant. Total ARF6 and ARF6-GTP were visualized by immunoblot analysis with an
anti-ARF6 mouse mAb. Densitometric analysis of ARF6-GTP is displayed as a histogram after normalizing to the expression of total ARF6 present in each
sample.
FIGURE 9. Schematic representation of the ARF6 signaling pathway
involved in HLHCGR internalization as deduced from the present study.
ARF6 Signaling in LHCGR Internalization
JUNE 8, 2012•VOLUME 287•NUMBER 24 JOURNAL OF BIOLOGICAL CHEMISTRY 20453
 by Venkateswarlu Kanam
arlapudi, on June 8, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
(an ARF GAP inhibitor). However Dynasore (dynamin inhibi-
tor), PBP10 (PIP2 inhibitory peptide) and the DN mutants of
NM23-H1 and EPS15 inhibited agonist-induced HLHCGR
internalization but not ARF6 activation. These results suggest
that the agonist binding to LHCGR results in Gs activation,
which then dissociates fromG and activates adenylyl cyclase.
G activates PI3K to produce the second messenger PIP3,
which recruits cytohesin ARF GEFs to the membrane for ARF6
activation.We suggest that ARF6-GTP then activates PIP5K to
produce PIP2, which recruits AP2 required for clathrin-coated
pit assembly. ARF6-GTP also recruits NM23-H1 to clathrin-
coated pits to provide GTP to dynamin dependent fission of
clathrin-coated vesicles (see explanatory diagram, Fig. 9).
These findings increase our understanding of the molecular
mechanisms underlying the ARF6-dependent regulation of
agonist-induced internalization of LHCGR, which is the most
important contributor to the down-regulation of the receptor.
In addition we suggest that the pathway described is likely to be
utilized by a range of GPCRs and thus be of general relevance to
receptor signaling and trafficking in cells.
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1Supplemental Figures 
Figure S1.  Concentration- and time-dependent internalisation of HLHCGR and cAMP 
production in HEK-HLHCGR cells stimulated with HCG.  A. HCG-stimulated loss of cell surface
HLHCGR as determined by ELISA. Cells were incubated with (i) different concentrations of HCG for 
30 min or 10 IU/ml HCG for 0-60 min.  Open symbols indicate cells incubated in the absence of HCG.  
B. Immunofluorescence analysis of HLHCGR internalisation in cells incubated with or without 
agonist as shown.  HEK-HLHCGR cells were incubated with an anti-Myc mouse mAb at 4
o
C and then 
incubated without (-HCG) or with 10 IU/ml HCG (+HCG) for 60 min (i) or with HCG at the indicated 
concentrations for 30min or 10 IU/ml HCG for 0-60 min (iii) at 37
o
C.  The cells were then fixed, 
permeabilised and immunostained using FITC-conjugated anti-mouse secondary antibody and the 
staining visualised by confocal microscopy.  C. Concentration- and time dependent cAMP 
accumulation by HCG. Cells were incubated with (i) different concentrations of HCG for 30 min or 10 
IU/ml HCG for 0-60 min. Open symbols indicate cells incubated in the absence of HCG.The 
concentration- and time- dependence of HCG-stimulated cAMP production.  HEK-HLHCGR were 
serum starved and stimulated without () or with HCG () at a concentration of 0.01-1000 IU/ml for 
30 min (i) or 10 IU/ml for 0-60 min. 
Figure S2.  Effect of QS11 (ARF GAP inhibitor) and BFA on HCG-induced HLHCGR 
internalisation and cAMP accumulation. A. HEK-HLHCGR cells pre-incubated with either BFA 
(1-50µg/ml, , ) or QS11 (0.1-12.5µM, ∆, ) for 30 min at 37oC were incubated without (open 
symbols) or with (solid symbols) 10 IU/ml HCG for 30 min at 37
o
C and receptor internalisation 
determined by ELISA.  B. Immunofluorescence analysis of the effect of QS11 and BFA on HCG-
stimulated (10 IU/ml HCG, 30 min) HLHCGR internalisation. C. cAMP accumulation in unstimulated 
(open symbols) or HCG-stimulated (solid symbols; 10 IU/ml HCG, 30 min) HEK-HLHCGR cells 
pretreated with the indicated concentrations of BFA or QS11 as described in part A above. 
Figure S3.  Effect of QS11 on ARF6 activation in HCG-stimulated HEK-HLHCGR cells.  HCG-
stimulated (10 IU/ml HCG, 30 min) ARF6 activation was assessed by a GST-GGA3 PBD pull down 
assay in HEK-HLHCGR cells preincubated with the indicated concentrations of QS11.  Total ARF6 
levels in the cell lysate and the resin bound ARF6-GTP were visualised by immunoblot analysis with 
an anti-ARF6 mouse mAb.  Densitometric analysis of ARF6-GTP is shown as a histogram after 
normalising to the expression of total ARF6 present in the sample.  Solid bars indicate measurements 
made in the presence of HCG.
Figure S4.  Effect of Dynasore on HCG-induced HLHCGR internalisation and cAMP 
accumulation.  A. HEK-HLHCGR cells were preincubated with Dynasore (16-400 µM) for 15 min at 
37
o
C, and were assayed by ELISA for loss of the cell surface receptor both in the absence () and in 
the presence () of 10 IU/ml HCG, 30 min.  B. Immunofluorescence analysis showing the inhibition 
of HCG-stimulated (10 IU/ml HCG, 30 min) HLHCGR redistribution by 80 µM Dynasore.  C. 
Concentration-dependent effect of Dynasore on cAMP accumulation in HEK-HLHCGR cells 
incubated without (∆) or with () 10 IU/ml HCG for 30 min.  D. Using a GST-GGA3 PBD pull down 
assay, the levels of endogenous ARF6-GTP under basal conditions and in the presence of HCG (10 
IU/ml HCG, 30 min) were not affected by Dynasore.  Total ARF6 and ARF6-GTP were visualised by 
immunoblot analysis with an anti-ARF6 mouse mAb.  Densitometric analysis of ARF6-GTP is 
displayed as a histogram after normalising to the expression of total ARF6 present in each sample. 
Figure S5.  Effect of PBP10 on HCG-induced HLHCGR internalisation and cAMP 
accumulation.  A. HEK-HLHCGR cells preincubated with PBP10 (0.01-10µM) for 15 min at 37
o
C 
were assayed by ELISA for loss of surface receptor both in the absence () and presence () of HCG 
(10 IU/ml HCG, 30 min)..  B. Immunofluorescence analysis showing the inhibition of HCG-
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2stimulated (10 IU/ml HCG, 30 min) HLHCGR redistribution by 1 µM PBP10.  C. Effect of PBP10 
(0.001-10 M)  on cAMP accumulation in unstimulated (∆) or 10 IU/ml HCG-stimulated () HEK-
HLHCGR cells.  PBP10 had a concentration-dependent stimulatory effect on HCG-induced cAMP 
accumulation.  D. Using a GST-GGA3 PBD pull down assay, the levels of endogenous ARF6-GTP 
under basal conditions and in the presence of HCG (10 IU/ml HCG, 30 min) were not affected by 
PBP10.  Total ARF6 and ARF6-GTP were visualised by immunoblot analysis with an anti-ARF6 
mouse mAb.  Densitometric analysis of ARF6-GTP is displayed as a histogram after normalising to 
the expression of total ARF6 present in each sample. 
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